Integra LifeSciences Holdings Corporation
NASDAQ:IARTMedical - Devices
+$0.81 today
- Market cap
- $1.08B
- Beta
- 1.25
- P/E (TTM)
- -2.8
- EPS (TTM)
- -$6.44
Volume 0.58M
Average 0.96M
IART Capital Expenditures
Cash spent on property, plant, equipment, and other long-term assets.
Integra LifeSciences Holdings CorporationNASDAQ: IART
Capital Expenditures · Q1 FY2026 · quarter ended Mar 2026
Capital expenditures declines year over year
Q1 FY2026 capital expenditures of $14.85M (cash outflow) fell 48.7% year over year, behind the -36.2% change in trailing-twelve-month capital expenditures. Sequentially, it fell 52.7% from the prior quarter. Over 3 fiscal years it compounded at +26.6% a year.
Context
- Capital expenditures amounted to 5.8% of revenue in FY2025, down 0.6 pp from a year earlier.
- Capital expenditures grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -48.7% toward the trailing-twelve-month pace of -36.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Capital Expenditures history
USD · from the cash flow
- Latest · FY2025
- (95.64M) USD
- Year-over-year change
- +8.4%
| Period | Period end | Capital Expenditures | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (95.64M) | +8.4% |
| FY2024 | 2024-12-31 | (104.42M) | -56.2% |
| FY2023 | 2023-12-31 | (66.87M) | -42.0% |
| FY2022 | 2022-12-31 | (47.09M) | +2.1% |
| FY2021 | 2021-12-31 | (48.08M) | — |
Capital Expenditures vs competitors
How IART compares with its peers on the latest reported figures
- IART's LTM Mar 2026 capital expenditures of $81.57M is the 4th largest of the 11 companies compared; the peer median is $40.97M.
- Its year-over-year change of -36.2% is the 10th highest of 11, against a peer median of +12.3%.
- Capital expenditures amounts to 5.0% of revenue for IART, versus a peer median of 3.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $823M | +10.9% | +9.0% | 3.2% | |
| FY2025 | $433M | +13.6% | +6.5% | 7.0% | |
| LTM Jun 2026 | $159.8M | +5.3% | +30.5% | 5.1% | |
| LTM Mar 2026 | $81.57M | -36.2% | +26.6% | 5.0% | |
| LTM Mar 2026 | $44.61M | -35.8% | -10.0% | 5.7% | |
| LTM Mar 2026 | $43.41M | +287.0% | +53.9% | 9.5% | |
| LTM Mar 2026 | $38.54M | +25.2% | +14.3% | 4.7% | |
| LTM Mar 2026 | $18.92M | +27.6% | -3.1% | 1.4% | |
| LTM Sep 2026 | $6.32M | +72.9% | -43.9% | 2.4% | |
| LTM Mar 2026 | $1.39M | -69.4% | +10.5% | 1.1% | |
| LTM Jun 2026 | $480K | -9.8% | -37.9% | 0.6% | |
| Peer median (excluding IART) | $40.97M | +12.3% | +7.8% | 3.9% | |
Competitors are the stored peer set for IART. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 169.08M | 180.55M | 67.74M | (6.94M) | (516.47M) |
| Depreciation & Amortization | 119.84M | 118.3M | 123.51M | 140.89M | 151.83M |
| Deferred Income Tax | (2.76M) | (4.59M) | (11.89M) | (20.73M) | (66.26M) |
| Stock-Based Compensation | 36.21M | 27.73M | 20.14M | 24.38M | 18.58M |
| Change in Working Capital | 18.16M | (39.42M) | (81.57M) | (31.01M) | (33.74M) |
| Accounts Receivables | 7.27M | (33.91M) | 4.59M | 7.4M | (485K) |
| Inventory | 5.37M | (29.12M) | (59.77M) | (28.15M) | (46.76M) |
| Accounts Payables | 32.87M | 17.34M | (20.23M) | (2.67M) | 26.72M |
| Other Working Capital | (27.35M) | 6.27M | (6.17M) | (7.58M) | (13.22M) |
| Other Non-Cash Items | (28.1M) | (18.1M) | 22.02M | 22.79M | 496.44M |
| Operating Cash Flow | 312.43M | 264.47M | 139.96M | 129.38M | 50.38M |
| Capital Expenditures | (48.08M) | (47.09M) | (66.87M) | (104.42M) | (95.64M) |
| Acquisitions (Net) | (113.44M) | (27.55M) | 0 | (277.81M) | 0 |
| Purchases of Investments | 0 | (4.91M) | (32.69M) | (49M) | (19.43M) |
| Sales of Investments | 76K | 4.91M | 5.38M | 54.5M | 7M |
| Other Investing Activities | (55K) | 16.05M | 0 | (14.08M) | (14.2M) |
| Investing Cash Flow | (161.44M) | (58.58M) | (94.18M) | (390.81M) | (108.06M) |
| Debt Repayment | (100M) | (107.8M) | 54.5M | 299.37M | 46.75M |
| Common Stock Issued | 6.82M | 0 | 0 | 0 | 957K |
| Common Stock Repurchased | 0 | (125M) | (275M) | (52.47M) | (221K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (5.05M) | (24.62M) | (9.43M) | (9.04M) | (19.15M) |
| Financing Cash Flow | (98.23M) | (251.95M) | (229.93M) | 237.86M | 28.34M |
| Effect of Forex Changes | (9.48M) | (10.72M) | 3.89M | (6.46M) | 18.02M |
| Net Change in Cash | 43.28M | (56.79M) | (180.26M) | (30.03M) | (11.33M) |
| Free Cash Flow | 264.35M | 217.38M | 73.09M | 24.96M | (45.25M) |
Integra LifeSciences Holdings Corporation
NASDAQ:IART
Intrinsic Alpha fair value
Locked
Current Price
$13.86
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.